WEKO3
アイテム
{"_buckets": {"deposit": "b1f423ab-4d96-453f-9265-0295fb351321"}, "_deposit": {"created_by": 25, "id": "43750", "owners": [25], "pid": {"revision_id": 0, "type": "depid", "value": "43750"}, "status": "published"}, "_oai": {"id": "oai:shinshu.repo.nii.ac.jp:00043750", "sets": ["2668"]}, "author_link": ["169909", "169916", "169907", "169913", "169908", "169906", "169910", "169915", "169917", "169914", "169911", "169912"], "item_20002_biblio_info_27": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-09-26", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "1004", "bibliographicPageStart": "997", "bibliographicVolumeNumber": "76", "bibliographic_titles": [{"bibliographic_title": "CANCER CHEMOTHERAPY AND PHARMACOLOGY"}]}]}, "item_20002_creator_3": {"attribute_name": "作成者(その他言語)", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yamazaki, N."}], "nameIdentifiers": [{"nameIdentifier": "169906", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kiyohara, Y."}], "nameIdentifiers": [{"nameIdentifier": "169907", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uhara, H."}], "nameIdentifiers": [{"nameIdentifier": "169908", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukushima, S."}], "nameIdentifiers": [{"nameIdentifier": "169909", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uchi, H."}], "nameIdentifiers": [{"nameIdentifier": "169910", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibagaki, N."}], "nameIdentifiers": [{"nameIdentifier": "169911", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsutsumida, A."}], "nameIdentifiers": [{"nameIdentifier": "169912", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa, S."}], "nameIdentifiers": [{"nameIdentifier": "169913", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuyama, R."}], "nameIdentifiers": [{"nameIdentifier": "169914", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Y."}], "nameIdentifiers": [{"nameIdentifier": "169915", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tokudome, T."}], "nameIdentifiers": [{"nameIdentifier": "169916", "nameIdentifierScheme": "WEKO"}]}]}, "item_20002_date_19": {"attribute_name": "日付", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2018-10-31", "subitem_date_issued_type": "Created"}]}, "item_20002_description_14": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "PurposeIpilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.MethodsPatients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).ResultsData are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively.ConclusionIpilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients.", "subitem_description_type": "Other"}]}, "item_20002_description_20": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_20002_description_22": {"attribute_name": "その他の資源識別子", "attribute_value_mlt": [{"subitem_description": "CANCER CHEMOTHERAPY AND PHARMACOLOGY.76(5):997-1004(2015)", "subitem_description_type": "Other"}]}, "item_20002_full_name_16": {"attribute_name": "公開者(その他言語)", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "169917", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "SPRINGER"}]}]}, "item_20002_identifier_23": {"attribute_name": "資源識別子URI", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/10091/00020987"}]}, "item_20002_relation_31": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.ncbi.nlm.nih.gov/pubmed/26410424", "subitem_relation_type_select": "PMID"}}]}, "item_20002_relation_32": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1007/s00280-015-2873-x", "subitem_relation_type_select": "DOI"}}]}, "item_20002_rights_50": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made."}, {"subitem_rights": "© The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made."}]}, "item_20002_source_id_25": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0344-5704", "subitem_source_identifier_type": "ISSN"}]}, "item_20002_source_id_26": {"attribute_name": "処理レコードID(総合目録DB)", "attribute_value_mlt": [{"subitem_source_identifier": "AA00598397", "subitem_source_identifier_type": "NCID"}]}, "item_20002_text_52": {"attribute_name": "機関ID", "attribute_value_mlt": [{"subitem_text_value": "17"}]}, "item_20002_text_53": {"attribute_name": "コンテンツID", "attribute_value_mlt": [{"subitem_text_value": "oai:soar-ir.repo.nii.ac.jp:00020229"}]}, "item_20002_text_54": {"attribute_name": "コンテンツ更新日時", "attribute_value_mlt": [{"subitem_text_value": "2020-08-03T06:51:28Z"}]}, "item_20002_version_type_51": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"download_preview_message": "", "file_order": 0, "filename": "", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"url": "https://soar-ir.repo.nii.ac.jp/?action=repository_action_common_download\u0026item_id=20229\u0026item_no=1\u0026attribute_id=65\u0026file_no=1"}, "version_id": ""}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Ipilimumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Immune-checkpoint inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Melanoma Phase II study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Japanese patients", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma"}]}, "item_type_id": "20002", "owner": "25", "path": ["2668"], "permalink_uri": "https://shinshu.repo.nii.ac.jp/records/43750", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-09-04"}, "publish_date": "2020-09-04", "publish_status": "0", "recid": "43750", "relation": {}, "relation_version_is_last": true, "title": ["Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma"], "weko_shared_id": -1}
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
https://shinshu.repo.nii.ac.jp/records/43750
https://shinshu.repo.nii.ac.jp/records/43750c57de7fa-01a0-41d0-a68c-eef38dbed22c
名前 / ファイル | ライセンス | アクション |
---|---|---|
https://soar-ir.repo.nii.ac.jp/?action=repository_action_common_download&item_id=20229&item_no=1&attribute_id=65&file_no=1
|
|
Item type | Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-09-04 | |||||
タイトル | ||||||
タイトル | Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma | |||||
作成者(その他言語) |
Yamazaki, N.
× Yamazaki, N.× Kiyohara, Y.× Uhara, H.× Fukushima, S.× Uchi, H.× Shibagaki, N.× Tsutsumida, A.× Yoshikawa, S.× Okuyama, R.× Ito, Y.× Tokudome, T. |
|||||
公開者(その他言語) | ||||||
姓名 | SPRINGER | |||||
書誌情報 |
CANCER CHEMOTHERAPY AND PHARMACOLOGY 巻 76, 号 5, p. 997-1004, 発行日 2015-09-26 |
|||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Ipilimumab | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Immune-checkpoint inhibitor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Melanoma Phase II study | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Japanese patients | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | PurposeIpilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.MethodsPatients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).ResultsData are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively.ConclusionIpilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients. | |||||
日付 | ||||||
日付 | 2018-10-31 | |||||
日付タイプ | Created | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Article | |||||
その他の資源識別子 | ||||||
内容記述タイプ | Other | |||||
内容記述 | CANCER CHEMOTHERAPY AND PHARMACOLOGY.76(5):997-1004(2015) | |||||
資源識別子URI | ||||||
識別子 | http://hdl.handle.net/10091/00020987 | |||||
識別子タイプ | HDL | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0344-5704 | |||||
処理レコードID(総合目録DB) | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00598397 | |||||
PubMed番号 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | https://www.ncbi.nlm.nih.gov/pubmed/26410424 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s00280-015-2873-x | |||||
権利 | ||||||
権利情報 | © The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | |||||
権利 | ||||||
権利情報 | © The Author(s) 2015. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |